Disc Medicine Inc. has released a corporate presentation detailing the progress of their investigational agents, Bitopertin, DISC-0974, and DISC-3405. The presentation outlines updates on the clinical programs, including the NDA progress for Bitopertin in Erythropoietic Protoporphyria $(EPP.UK)$, the MF Anemia Phase 1b data for DISC-0974, and the Phase 2 study design for DISC-3405 in Polycythemia Vera. Additionally, the presentation includes insights into the commercialization planning and the potential for accelerated approval for certain programs. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。